Last reviewed · How we verify
Amoxicillin, Clarithromycin
Amoxicillin and clarithromycin are antibiotics that work together to inhibit bacterial protein synthesis and cell wall formation, commonly used in combination therapy for H. pylori eradication.
Amoxicillin and clarithromycin are antibiotics that work together to inhibit bacterial protein synthesis and cell wall formation, commonly used in combination therapy for H. pylori eradication. Used for Helicobacter pylori infection (as part of combination therapy), Respiratory tract infections, Gastrointestinal infections.
At a glance
| Generic name | Amoxicillin, Clarithromycin |
|---|---|
| Also known as | Supercillin, Klaricid |
| Sponsor | Mackay Memorial Hospital |
| Drug class | Beta-lactam antibiotic and macrolide antibiotic combination |
| Target | Bacterial cell wall (amoxicillin); bacterial 50S ribosome (clarithromycin) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Together, they provide synergistic antimicrobial activity and are frequently used as part of triple or quadruple therapy regimens for Helicobacter pylori infection.
Approved indications
- Helicobacter pylori infection (as part of combination therapy)
- Respiratory tract infections
- Gastrointestinal infections
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Vomiting
- Rash
- Allergic reaction
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial (NA)
- Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study
- Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1 (PHASE4)
- Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy (PHASE4)
- The Impact of Helicobacter Pylori Eradication on the Vaginal Microecology Change
- Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection (PHASE2)
- Fecal Molecular Susceptibility-guided Hp First-line Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amoxicillin, Clarithromycin CI brief — competitive landscape report
- Amoxicillin, Clarithromycin updates RSS · CI watch RSS
- Mackay Memorial Hospital portfolio CI